Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Yale University
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00338598CT.gov Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Alcohol Dependence
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Glycine (this asset) | Yale University | P2 | B · 57 |
| Naltrexone | Inventage Lab., Inc. | P4 | BBB |
| Acamprosate | Hanyang University Seoul Hospital | P4 | BBB |
| Escitalopram | University of Texas Southwestern Medical Center | P4 | BBB |
| Topiramate | Stanford University | P4 | BB |
| Fluoxetine | New York State Psychiatric Institute | P4 | BB |
| Lamotrigine | Medical University of South Carolina | P4 | BB |
| Quetiapine | University of Texas Southwestern Medical Center | P4 | BB |
| Varenicline | State University of New York - Upstate Medical University | P4 | BB |
+18 more in the Alcohol Dependence cohort
Other indications for Glycine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Schizoaffective Disorder | — | P2/3 | BBB · 74 |
| Schizophrenia | — | P3 | B · 63 |
| Psychotic Disorder | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Glycine in Alcohol Dependence. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/glycine-alcohol-dependence
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →